Exploratory biomarker findings from cohort 2 of MODUL: An adaptable, phase 2, signal-seeking trial of fluoropyrimidine plus bevacizumab +/- atezolizumab maintenance therapy for BRAF(wt) metastatic colorectal cancer
Tabernero, J., Grothey, A., Arnold, D., Ducreux, M., O’Dwyer, P. J., Perdicchio, M., . . . Van Cutsem, E. (2021). … Read More